克罗恩病 中国就医指南

Crohn's disease is a chronic, immune-mediated inflammatory bowel disease (IBD) characterized by transmural inflammation that can affect any segment of the gastrointestinal tract—from mouth to anus—but most commonly involves the terminal ileum and proximal colon. Unlike ulcerative colitis, which is limited to the mucosa and continuous in distribution, Crohn’s disease exhibits patchy, discontinuous lesions ('skip areas'), deep ulcerations, granulomas (in up to 30% of surgical specimens), and complications such as strictures, fistulas, and abscesses. Its pathogenesis involves a dysregulated immune response to commensal gut microbiota in genetically susceptible individuals—key susceptibility loci include NOD2/CARD15, ATG16L1, and IL23R—interacting with environmental triggers like smoking, Western diet (high in fat and refined sugars), antibiotic exposure in early life, and dysbiosis. Epidemiologically, Crohn’s disease has a bimodal age distribution (peaks at 15–30 years and 60–80 years), with an estimated global prevalence of 10–20 per 100,000 and incidence of 0.5–10 per 100,000 person-years. Prevalence is rising in newly industrialized regions—including parts of China—where urbanization and dietary shifts are accelerating IBD emergence. Major risk factors include cigarette smoking (doubles disease risk and worsens prognosis), family history (10–20% of patients have a first-degree relative with IBD), appendectomy before age 20 (modest protective effect), and vitamin D deficiency. Beyond physical morbidity—recurrent abdominal pain, diarrhea (often bloody), weight loss, fatigue, and extraintestinal manifestations (e.g., erythema nodosum, uveitis, ankylosing spondylitis)—Crohn’s disease profoundly impacts quality of life. Patients report high rates of anxiety and depression (up to 40%), reduced work productivity, social withdrawal due to unpredictable symptoms and fecal urgency, and diminished health-related quality of life scores comparable to those seen in end-stage renal disease or advanced heart failure. Pediatric-onset disease carries additional burdens: growth failure, delayed puberty, and long-term educational and psychosocial consequences. Early diagnosis and proactive, individualized management—including nutritional support, immunomodulators, biologics (anti-TNF, anti-integrin, anti-IL-12/23 agents), and timely surgical intervention when indicated—are critical to achieving mucosal healing, preventing complications, and preserving intestinal function over decades.

# 克罗恩病治疗方案与费用明细（消化内科）

一、非手术保守治疗（一线首选）

• •适用人群：轻中度活动期、无狭窄/穿孔/脓肿者
• •药物方案：

- 糖皮质激素（泼尼松）：80–200元/月（短期诱导缓解） - 免疫抑制剂（硫唑嘌呤/甲氨蝶呤）：400–1200元/月 - 生物制剂（英夫利西单抗/阿达木单抗）：首年12–25万元（含输注/皮下注射及监测）

• •检查费：肠镜+活检（1800–2600元）、粪钙卫蛋白（280元）、CRP/ESR/肝肾功（150元）、血药浓度监测（硫唑嘌呤/他克莫司：300–500元/次）

二、手术治疗（并发症或药物难治者）

• •适用条件：肠梗阻、瘘管、脓肿、癌变或顽固性出血
• •术式与费用：

- 肠造口术（临时/永久）：3.5–5.3万元 - 瘘管切除+引流术：3.8–6.1万元

三、特殊复杂情况处理

• •难治性/耐药/肛周瘘管：联合生物制剂+抗生素+营养支持，年均费用15–30万元
• •重度活动伴中毒性巨结肠：急诊手术+ICU监护，单次总费用8–12万元

四、方案快速选择指南

• •预算有限（≤2万/年）：美沙拉嗪+激素+定期随访（限轻症）
• •中等预算（5–15万/年）：免疫抑制剂+规范内镜监测（适中重度）
• •高需求/复杂瘘管/反复复发：生物制剂+多学科管理（推荐三甲消化中心）
• •急症并发症：立即转诊至具备IBD外科能力的三甲医院消化内科/胃肠外科联合诊疗